Responding to regional advancements in combating measles, the World Health Organization called for an assessment of the feasibility of eradication, including whether sufficient vaccine supply exists. Interviews with international health officials and vaccine-makers provided data for a detailed model of worldwide demand and supply for measles-containing vaccine (MCV). The study projected global MCV demand through 2025 with and without a global eradication goal. The study found that 5.2 billion cumulative MCV doses must be administered in 2010-2025 to maintain current measles programs, while 5.9 doses would likely be needed with a 2020 eradication goal; demand could rise to 7.5 billion in an upper-bound eradication scenario. These volumes are within existing and planned MCV-manufacturing capacity, though there are risks. In some markets, capacity is concentrated:
programmatic, economic, political, and biological factors; impact on healthcare systems; and potential risks to the vaccine supply [1] . This current study was designed to answer four questions:
• What is the likely global demand for MCV under current programs for controlling measles?
• How might demand change with a 2020 eradication goal?
• Would aggregate manufacturing capacity, for each vaccine type-monovalent measles (M), measles-rubella (MR), and mumps-measles-rubella (MMR)-be sufficient to support a global eradication effort?
• Are there any risks associated with MCV supply that warrant further evaluation?
This study, completed in September 2009, focused on the 2010-2025 time frame and considered the global demand implications of setting a 2020 measles eradication goal, the vaccine capacity needed, and the potential supply risks. This paper summarizes those findings and compares the resources required for eradication against baseline immunization activities already instituted or planned.
Methods

Demand projections
WHO recommends the provision of 2 doses of MCV to all children either through routine immunization systems or nationwide campaigns * (also known as supplemental immunization activities or SIAs) [2] . With these WHO recommendations as a guide, we developed a set of demand projections through a series of interviews conducted during the winter and summer of 2009 with 39
experts: WHO officials from each regional office and select countries and Supply Division personnel from the United Nations Children's Fund (UNICEF), as well as authorities on global measles disease burden, epidemiology and control. With these stakeholders, the project team first identified key demand drivers-the set of immunization activities currently employed or that may be needed in the future. The team first worked with experts to project future MCV demand in the absence of a global eradication goal. Here, respondents provided data on each demand driver, including trends in immunization activity coverage rates as well as SIA requirements, planned or potential shifts in delivery strategies, and vaccine product mix (e.g., moving from M to MR). This information was tabulated country by country.
These data were transferred into a proprietary Microsoft Excel-based model to allow the project team to evaluate the impact of MCV demand drivers and develop a picture of future MCV demand in the "base case," without a global eradication goal. These data were merged with other country-level inputs, including population data (e.g., size of birth cohort, age/sex bands) and historical information on coverage rates, SIAs, and type of vaccine used [3] . For the purposes of projecting future coverage rates, all countries were grouped using their historical coverage rates into three categories (see Table   1 ): High (defined as countries whose coverage rates exceeded 90% for the last three years, n=123); * Campaigns or SIAs are generally carried out using 2 approaches. An initial, nationwide catchup campaign targets all children aged 9 months to 14 years; it has the goal of eliminating susceptibility to measles in the general population. Periodic follow-up campaigns then target all children born since the last campaign. Follow-up campaigns are generally conducted nationwide every 2-4 years and target children aged 9-59 months; their goal is to eliminate any measles susceptibility that has developed in recent birth cohorts and to protect children who did not respond to the first measles vaccination.
Growth (countries whose rates are still below 90% but have increased over the last three years, n=24); Plateau (countries whose rates are still below 90% and have not increased meaningful over the last three years, n=48). In the base case scenario, we assumed coverage rates for countries in the High and Plateau categories would continue at a three year average of each country's historical rates. For those countries in the Growth category, we assumed each country's coverage rate would continue to rise according to a logarithmic regression calculated separately for each country (typical R 2 was greater than 90%).
Once base case demand had been projected country by country and globally, the team conducted follow-up interviews with 22 of the 39 experts to explore the conditions necessary to eradicate measles by 2020. Each respondent provided data on the incremental country-specific immunization activities they felt would be required. These findings were incorporated into the model and served as the basis for developing eradication-demand projections. To model coverage rate growth under elimination, the project team constructed an s-curve with a peak value of 95% through consultation with select members of the expert panel. Each country's starting position on the curve was determined using its current coverage rates. Generally speaking, those countries with current routine immunization coverage rates greater than 90% were projected to reach 95% in 3 years; those with rates around 80% were projected to reach 95% in 7 years; those with rates less than 70% were projected to reach 95% in 10 years.
Supply capacity
To evaluate worldwide MCV supply, the project team first engaged the UNICEF Supply Division, WHO, and industry experts to pinpoint existing and potential sources of MCV. The team then canvassed secondary sources (e.g., WHO prequalification submissions, intellectual property Web sites and databases including WIPO and Google Patents, and vaccine literature referencing MCV suppliers [4] ) to form a more robust list. Once a comprehensive supply base had been identified, the team interviewed 10 current and potential MCV manufacturers to map overall supply dynamics. In particular, these discussions focused on defining existing capacity levels, estimating planned or potential capacity changes over the next 10-15 years, and identifying critical decision points related to those capacity changes. To complement direct manufacturer dialogues and build a more holistic perspective, the project team reengaged the representatives from the UNICEF Supply Division and WHO.
As a final step, the team segmented the global market and mapped demand against relevant or accessible supply. This segmentation was necessary because MCV sources do not necessarily serve all segments of demand (for example, some national suppliers serve their domestic markets exclusively and do not export). With this map complete, the team assessed potential supply gaps and risks within each demand segment. For reasons of confidentiality, and because some markets are served by so few suppliers, this report does not cover manufacturing capacity at the segment level.
Results
Global demand segmentation.
Global demand falls naturally into five segments, each characterized by its dominant vaccine type and/or vaccine-supply modality (Tables 2 and 3 ). This paper will generally report demand at the segment level.
• Developed World, primarily high-income countries in North America and Europe, using MMR vaccines (containing Jeryl Lynn or Jeryl Lynn-like mumps strains) from large, multinational manufacturers.
• Self-Suppliers, middle-and low-income countries obtaining their vaccines almost exclusively from domestic manufacturers (which may or may not be government •
Rest of World MMR, primarily middle-income countries in the Americas and Eastern
Mediterranean WHO regions, obtaining MMR (with non-Jeryl Lynn-like mumps strains) from WHO prequalified manufacturers.
• Rest of World MR, primarily UNICEF-supplied middle-and low-income countries using MR vaccines from WHO prequalified manufacturers.
• Rest of World M, UNICEF-supplied middle-and low-income countries using M monovalent vaccine obtained from WHO prequalified manufacturers.
Without eradication, vaccine demand will decrease slightly and flatten out. The mix of vaccine types will remain essentially static.
As catch-up SIAs wind down in the absence of an eradication goal, annual MCV demand will likely decrease and remain relatively flat. This will still be the case even with several regions continuing to pursue measles elimination or control strategies. Cumulative vaccine demand from 2010 through 2025 will total about 5.2 billion doses. In this scenario, the overall vaccine mix will likely change little (see Table 4 ). . For these countries, the adoption decision is driven by an assessment of local rubella disease burden and desire to address it. The decision is not very sensitive to the availability of donor funding for rubella vaccine costs; most of the expected adopting countries are eligible for assistance from the Global Alliance for Vaccines and Immunisation (GAVI). In transitioning to MR, these countries are expected to follow current WHO and regional policy recommendations, conducting rubella catch-up SIAs targeting women of childbearing † We assumed countries will transition from M to MR or MMR when they obtain MCV1 coverage of greater than 80 percent for at least three consecutive years. Eradication is expected to raise MCV demand by ~700 million doses.
The number of catch-up
With a global eradication goal, the study forecasts that from 2010 through 2025 cumulative MCV demand will be 5.9 billion doses, a 13.5 percent increase over the base case. Global eradication would affect several key demand drivers (see Table 5 ). The anticipated increase in demand would, however, be overwhelmingly driven by the potential need for additional catch-up SIAs.
Overall demand and vaccine mix is minimally sensitive to differing MCV1 and MCV2 delivery
strategies. Based on consistent feedback from the advisory panel, the study team assumed that eradication in all countries would require two MCV immunization doses per child. WHO and UNICEF personnel at the regional and country level would universally target a strategy of two routine doses (MCV1/MCV2) with 95 percent coverage rates. Based on current coverage rates, realization of this delivery strategy would require 115 countries to increase their coverage rates, some quite rapidly.
Given this, some respondents suggested attaining sufficiently high coverage rates may be more effective via a hybrid strategy: routine MCV1 with periodic follow-up supplemental immunization ‡ The 18 Indian states are not expected to conduct rubella catch-up campaigns. In an upper-bound eradication scenario, demand could climb an incremental 1,600 million doses.
As . In this extreme case, cumulative MCV demand would increase another ~1,000 million doses.
All told, 5.9-7.5 billion doses of MCV could be required to pursue a global eradication goal, which would constitute an increase of 700 million to 2,300 million doses over the base case (13.5-44.2 percent higher). § The specific timing of these campaigns was undefined; assumed to be spread evenly over 2015-2020.
Global production capacity could meet the demands of eradication.
Projected MCV supplies would be sufficient to meet both the expected and upper-bound vaccine demands of an eradication program, though supply risks exist in some segments. Figure 1 shows year-by-year demand for each type of vaccine in each of the five global supplymodality segments. Considering the high stakes of global eradication, it is necessary to evaluate MCV supply using two criteria: the ratio of capacity to demand (requiring an understanding of the manufacturer landscape, current and potential capacities, and each manufacturer's market) and the risks to the stability of supply, both in terms of physical capacity and price.
Developed World. Overall supply risk: low. Though only two suppliers serve this segment, their available capacity is more than sufficient to support the 2020 eradication goal. One supplier currently controls most of the manufacturing capacity, but the secondary player could add capacity for equal output. that improved the supply outlook. The dominant supplier has taken several steps to minimize the probability and the impact of a supply disruption-creating redundancy and diversity in its supply chains, increasing the number of its production facilities, and increasing inventories of bulk and filled product. Further, the supplier thought to be at risk of exiting the market is likely to stay. All told, the segment's overall annual capacity has the potential to expand from ~400 million to ~500 million doses within the next two to four years. These levels would be more than sufficient to support global eradication scenarios. In the expected eradication scenario, all three suppliers could play approximately equal roles, minimizing risk. Sufficient capacity would still exist to supply the upperbound eradication scenario, but the dominant supplier would take on a larger role.
Self-Suppliers. Overall supply risk: low to moderate. By definition, in-country
Discussion: A Way Forward
In aggregate, projected near-term M, MR, and MMR manufacturing capacity would be sufficient to meet projected demand in the event of a 2020 eradication goal. The primary supply risk is the concentration of manufacturing capacity, which poses concerns over the certainty of supply and the long-term stability of price. The degree of concentration does vary across demand segments and vaccine types (i.e., M, MR, and MMR) and in total, represents a low to moderate global risk to requisite supply.
It is important for countries and the community at large to assess their supply-risk tolerance with and without the eradication goal. Depending on that threshold and the perceived risks, stakeholders could pursue several risk-mitigating options. They might, for example, stockpile inventory at strategic points in the supply chain. This buffer stock would reduce the impact of supply disruption (e.g., a manufacturing facility problem) or an unexpected surge in demand (e.g., a large measles outbreak).
More work is needed to determine appropriate inventory levels, locations, and financing mechanisms.
To address price stability risk, stakeholders might enter into long-term supply contracts, committing to set volumes at set prices. This would create greater cost transparency in an effort to secure sufficient advance financing. Moreover, to address both supply certainty and pricing risks, "self-supply" manufacturers could be encouraged to export products, temporarily or long-term. Many of these suppliers would first need to obtain WHO prequalification for their products, and the amount actually available for export would depend on domestic needs. In addition, the cost of vaccine from these sources is not entirely known and should be investigated further.
No matter the course of action, it will be important to continually refine forecasts of demand related to global eradication and establish mechanisms for quickly communicating forecast changes to existing and potential manufacturers. Adequate warning will give them enough time to act (e.g., make capacity adjustments) and ultimately ensure that supply and demand are well matched.
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